本帖最后由 老马 于 2012-1-13 21:20 编辑 " P' X; V( i D$ P( I& R% k, ]
9 O' g" k0 C, I' F2 V9 m爱必妥和阿瓦斯丁的比较1 L1 [8 H6 U4 R" G; q
$ P% s' d6 }! \ s. J- W% ]+ F
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/$ ~; C! z& B( r. L/ S4 e: E, z; j
1 E5 N- ?* y+ p
) P. Y' G! r% x8 Z6 }% A/ g
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ ]8 Z" e) J& i- p9 H
==================================================( N+ {% @- l5 S6 s' u, h
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)& R3 s3 ], n6 a. A; H$ b2 ]
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.- W0 g8 p+ l7 i, t- I( {1 @
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.+ `0 l- N3 R- w/ I, H
|